TABLE 2.
Brief survey of on-market or in-development checkpoint inhibitors with HIV-targeting potential
| Stage | Checkpoint | Inhibitor(s) | Trial(s) (phase) |
|---|---|---|---|
| On market | PD-1 | Pembrolizumab (Keytruda), nivolumab (Opdivo) | |
| PD-L1 | Atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) | ||
| CTLA-4 | Ipilimumab, MDX-010 (Yervoy), tremelimumab (orphan designation) | ||
| In trials | TIGIT | BMS-986207 | NCT02913313 (1/2) |
| OMP-313M32 | NCT03119428 (1) | ||
| MTIG7192A | NCT02794571 (1) | ||
| Tim-3 | TSR-022 | NCT02817633 (1) | |
| LAG3 | Relatlimab (previously BMS-986016) | 11 clinical trials (1, 1/2, 2/3) | |
| GITR | TRX518 | NCT01239134 (1), NCT02628574 (1) | |
| Preclinical | Anti-CD160 | ELB021 (Elsalys Biotech) | |
| Anti-BTLA | 40E4 chimericIgG1 (Merck & Co.) |